- Home
- VCRE vs EU Comparison
VCRE vs EU Comparison
Compare VCRE & EU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VCRE | EU |
|---|---|---|
| Founded | N/A | 2009 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | | Other Metals and Minerals |
| Sector | | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.9M | 306.9M |
| IPO Year | 2026 | 2011 |
Fundamental Metrics
Financial Performance| Metric | VCRE | EU |
|---|---|---|
| Price | $11.07 | $1.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 7.7K | ★ 3.5M |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,155,000.00 |
| Revenue This Year | N/A | $212.11 |
| Revenue Next Year | N/A | $29.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.50 | $1.03 |
| 52 Week High | $13.15 | $4.19 |
Technical Indicators
Market Signals| Indicator | VCRE | EU |
|---|---|---|
| Relative Strength Index (RSI) | 40.71 | 48.80 |
| Support Level | $10.83 | $1.03 |
| Resistance Level | $13.00 | $1.47 |
| Average True Range (ATR) | 0.73 | 0.09 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 20.00 | 40.43 |
Price Performance
Historical ComparisonAbout VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
About EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is principally engaged in the acquisition, exploration, development and extraction of uranium resource properties in the United States. The Company is focused on the extraction of domestic uranium in the United States. The Company utilizes the In-Situ Recovery technology (ISR) to provide necessary fuel for the generation of clean, reliable, and carbon-free nuclear energy.